Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 9.30 Billion | USD 13.96 Billion | 4.1% | 2024 |
The global pruritus therapeutics market size was worth around USD 9.30 Billion in 2024 and is predicted to grow to around USD 13.96 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 4.1% between 2025 and 2034.
The report analyzes the global pruritus therapeutics market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the pruritus therapeutics industry.
Pruritus is an unpleasant sensation and a most common skin disease symptom leading an individual to scratch skin. It is a cutaneous symptom and if it is ignored can lead to chronic pain as well as severely impact quality of life. For instance, pruritus can cause sleep disturbance, anxiety, and attention-deficit or hyperactivity disorder. Furthermore, if left untreated it can cause psychiatric and systemic ailments. According to NIH researchers, studies have revealed that hemodialysis individuals prone to more itching have more probability that their lifespan can be reduced.
Furthermore, chronic pruritus, which is one of the key dermatology symptoms, is intractable and has a huge impact on quality of life. Apart from this, the ailment is associated with psychological, systemic, and neurologic disorders. As per reports, the pathogenesis of chronic pruritus is acute and can result in inflammation in cell tissues. Additionally, an increase in knowledge of chronic pruritus pathogenesis coupled with access to high-quality data from clinical experiments has resulted in the emergence of new therapies for treating pruritus.
These drug treatments are also anticipated to be utilized in routine dermatology medical practice. They are opioidergic medicines such as kappa-opioid agonists & mu-opioid antagonists, Janus Kinase inhibitors, neurokinin-1 receptor antagonists, biologic medicines, histamine H4 receptor antagonists, ileal bile acid transport inhibitors, and aryl hydrocarbon receptor agonists.
A rise in the occurrence of skin itching symptoms causing psoriasis, dermatitis, and urticarial will drive pruritus therapeutics market growth. In addition to this, high unmet healthcare requirements and the launching of novel products including Bilastine and REMITECH drugs are predicted to contribute majorly towards market profits. Low drug costs and the willingness of subjects to take treatment will prompt the expansion of the industry in the next few years. High opportunity costs for treating skin diseases such as psoriasis will proliferate the expansion of the pruritus therapeutics industry over the ensuing years.
In addition to this, large-scale use of barrier repair creams, moisturizers, and emollients is a key to pruritus treatment and helps in minimizing pruritus with the help of enhanced barrier activities. Furthermore, topical corticosteroids are utilized to provide relief to patients having itching sensations and inflammatory skin ailments including psoriasis. However, topical calcineurin inhibitors, pimecrolimus, and tacrolimus have proved to be effective in alleviating pruritus in subjects suffering from atopic dermatitis. Additionally, azathioprine, doxepins, cyclosporine, oral antihistamines, menthol, capsaicin, topical salicylic acid, neuroleptics, aprepitant, and topical cannabinoids have proved effective in the treatment of pruritus. All these aforementioned aspects will result in an enlarged expansion of the pruritus therapeutics market. Clinical studies have proved that drugs such as NGX-100, TS-022, and Methylnaltrexone have huge potential to effectively treat pruritus, thereby steering market trends.
Pruritus is the medical term for itchy skin. Pruritus is the most common dermatological disorder. Pruritus is a normal body reaction to protect from harmful external parasites or substances such as insect bites. However, it can be a result of a wide range of skin diseases. Pruritus lasting for more than 6 weeks is called chronic pruritus. Pruritus has been classified into the following four key types neuropathic, cutaneous, psychogenic and neurogenic. Chronic renal failure is a vital cause of persistent pruritus. Pruritus is enhanced or provoked by several chemical substances such as prostaglandins, cytokines, histamine, proteases, neuropeptides and bile salts. Furthermore, chronic pruritus is becoming a burden to society mainly due to the treatment-related costs, which are particularly high due to the elevation rate of therapeutic failure.
The global pruritus therapeutics market is segmented based on Product, Disease Type, and region.
Based on Product, the global pruritus therapeutics market is divided into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, and Calcineurin Inhibitors.
On the basis of Disease Type, the global pruritus therapeutics market is bifurcated into Atopic Dermatitis, Allergic Contact Dermatitis, and Urticaria.
Report Attributes | Report Details |
---|---|
Report Name | Pruritus Therapeutics Market |
Market Size in 2024 | USD 9.30 Billion |
Market Forecast in 2034 | USD 13.96 Billion |
Growth Rate | CAGR of 4.1% |
Number of Pages | 185 |
Key Companies Covered | Brunswick Corporation, Precor Incorporated, Johnson Health Tech Co. Ltd., Technogym, Nautilus Strength, Icon Health & Fitness, Amer Sports Oyji, and Cybex International Inc., and others., and others. |
Segments Covered | By Product, By Disease Type, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America To Account Majorly Towards Regional Market Share By 2034
Growth of the regional market over the forecasting timeline can be credited to the launching of new therapeutic products and approval of generic medicines by the U.S. FDA for treating pruritus & chronic pruritus such as psoriasis.
Apart from this, supportive government regulations of pruritus treatment will spur regional market surges. According to NIH researchers, in 2011, the occurrence of psoriasis in the U.S. was nearly 20% in children and about 4% in grown-ups.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the pruritus therapeutics market on a global and regional basis.
The global pruritus therapeutics market is dominated by players like:
The global pruritus therapeutics market is segmented as follows;
By Product
By Disease Type
By Region
FrequentlyAsked Questions
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed